Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

Abstract Background Urothelial carcinoma (UC) is the second most common malignancy of the urinary system with high rate of recurrence, UC patients therefore needed to be treated with surgery followed by chemotherapy. Development of novel therapeutics with minimal side-effect is an urgent issue. Our...

Full description

Bibliographic Details
Main Authors: Yeong-Chin Jou, Guan-Ling Lin, Hon-Yi Lin, Wan-Hong Huang, Yu-Ming Chuang, Ru-Inn Lin, Pie-Che Chen, Shu-Fen Wu, Cheng-Huang Shen, Michael W. Y. Chan
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Cancer Cell International
Subjects:
Cyproheptadine
Epigenetics
IRF6
Urothelial carcinoma
Online Access:https://doi.org/10.1186/s12935-021-01925-9

Similar Items

Similar Items